Complex karyotype (CK) is a negative prognostic factor in chronic lymphocytic leukaemia (CLL). However, CK is a heterogeneous cytogenetic category. Unbalanced rearrangements were present in 73Á3% of 90 CLL patients with CK (i.e. ≥3 chromosome aberrations in the same clone), and were associated with a shorter overall survival (P = 0Á025) and a shorter time to first treatment (P = 0Á043) by multivariate analysis. Patients with unbalanced rearrangements presented a distinct mRNA expression profile. In conclusion, CLL patients with unbalanced rearrangements might represent a subset of very high-risk CLL patients with distinct clinical and biological characteristics.
with CLL (CLL-IPI) (Rigolin et al, 2017a) and of high-risk CLL features, including unmutated IGHV genes and/or 11q/ 17p deletions (Rigolin et al, 2017b) .
CLL patients with CK may present a variety of cytogenetic aberrations, including numerical (i.e. monosomies and trisomies) and structural abnormalities (i.e. balanced and unbalanced translocations, derivative or marker chromosomes, isochromosomes, deletions, insertions and additions). It is unknown whether specific cytogenetic patterns within the CK may correlate with the clinical outcome.
We therefore investigated whether the presence of numerical or structural chromosomal abnormalities could be associated with distinct clinical or biological features in CLL patients with a CK.
Materials and methods

Patients
The study cohort included 90 patients with untreated CLL and a CK, diagnosed between 2000 and 2017. All patients were diagnosed and treated according to National Cancer Institute criteria (Hallek et al, 2008) . The local ethics committee approved the study.
Cytogenetic analyses
Cytogenetic analysis was performed on PB samples and a karyotype was defined as complex in the presence of at least 3 chromosome aberrations in the same clone, as described by Rigolin et al (2017a) . The following cytogenetic aberrations, each occurring at least in five patients, were considered: monosomies, trisomies, deletions, balanced translocations, unbalanced rearrangements (including chromosome additions, derivatives, insertions, duplications, ring, dicentric and marker chromosomes) and the presence of ≥5 abnormalities.
IGHV status, mutational analyses and gene expression profile (GEP) analysis IGHV genes were amplified from genomic DNA and sequenced according to standard methods with the cut-off of 98% homology to the germline sequence to discriminate between mutated (<98%) and unmutated (≥98%) cases, as previously reported (Rigolin et al, 2015) . Mutations of NOTCH1, SF3B1, BIRC3 and TP53 genes were analysed by next generation sequencing analysis using Ion Torrent PGM (Life Technologies, Foster City, CA), as described elsewhere (Rigolin et al, 2016) . Details of GEP analysis are reported in Supplemental Methods (Appendix S1).
Statistical analysis
Fisher's exact test was applied for categorical variables. Timeto-first treatment (TTFT) was calculated as the interval between diagnosis and the start of first line treatment. Overall survival (OS) was calculated from the date of diagnosis until death due to any cause or until the last patient followup. Proportional hazards regression analysis was used to identify the significant independent prognostic variables on TTFT. The stability of the Cox model was internally validated using bootstrapping procedures (Rigolin et al, 2017b) . Statistical analysis was performed using Stata 14Á0 (Stata Corp., College Station, TX).
Results
Patients and outcome
Patients' characteristics are reported in Table I . The median age of this CLL cohort was 67Á4 years (range 40-94) and the median period of follow-up was 51Á3 months.
In univariate analysis (Table II) , an inferior OS was associated with age >65 years (P = 0Á007), unbalanced rearrangements (P = 0Á015) and the presence of 5 or more abnormalities (P = 0Á021). Multivariate analysis (Table II) confirmed age >65 years (P = 0Á038) and unbalanced rearrangements (P = 0Á025; Figure S1A ) to have a negative prognostic impact on OS.
A list of the karyotype abnormalities and of their distribution according to the presence of unbalanced rearrangements is presented in Table SI .
The principal clinical and biological characteristics of the patients with and without unbalanced rearrangements are reported in Table I . Patients with unbalanced rearrangements had a lower incidence of 11q deletion (P = 0Á029) and trisomies (P = 0Á006) and a higher incidence of TP53 aberrations (P = 0Á014), monosomies (P = 0Á004) and a karyotype with more than 5 abnormalities (P = 0Á003).
When considering TTFT, in univariate analysis (Table II) , an inferior outcome was associated with advanced Binet stage (P = 0Á003), unmutated IGHV (P = 0Á009) and unbalanced rearrangements (P = 0Á018; Figure S1B ). In multivariate analysis (Table II) , advanced stage (P = 0Á001), unmutated IGHV (P = 0Á034) and unbalanced rearrangements (P = 0Á043) retained their negative prognostic impact on TTFT.
Gene expression profiling (GEP)
The analysis of mRNA expression profiles of 23 patients with (n = 11) and without (n = 12) unbalanced rearrangements identified 160 differentially expressed genes (P < 0Á1, fold change cut-off >2Á0). The cases investigated were representative of the entire cohort in terms of age, stage, TTFT and survival. A list of the most up-and down-regulated genes with the corresponding gene functions and deregulated pathways is reported in Table S2 . Using this combined set of genes, a clear-cut separation of the analysed samples was evident ( Figure S2) . A heat-map representation of the average expression of the 30 most differentially expressed genes between patients with and without unbalanced rearrangements is presented in Figure S3 . Among the differentially expressed mRNAs, there were genes involved in the response to DNA damage and cell cycle regulation.
Discussion
A CK is found in 10-15% of CLL (Baliakas et al, 2014; Rigolin et al, 2015) and has been associated with an inferior outcome when present at diagnosis (Baliakas et al, 2014; Rigolin et al, 2017a) , disease progression (Herling et al, 2016) or in relapsed/refractory patients treated with ibrutinib (Thompson et al, 2015) or venetoclax (Anderson et al, 2017) . Interestingly, in high-risk CLL (Rigolin et al, 2017b) , the prognostic impact of a CK was independent of TP53 status, while a CK has been associated with a stronger prognostic significance than TP53 aberrations in relapsed/refractory CLL treated with novel agents (Thompson et al, 2015; Anderson et al, 2017) . We found that, in CLL patients with CK, unbalanced rearrangements were independently associated with a worse OS and TTFT and that they identified a subset of patients with distinct features, including a lower incidence of 11q deletions and a higher incidence of TP53 aberrations (17p deletions and/or TP53 mutations). Moreover, the negative prognostic impact of unbalanced rearrangements was independent of the TP53 status.
In CLL patients, conventional cytogenetics with novel mitogens represents a robust and valuable tool for a more precise refinement of prognosis. It enables the identification of, not only a CK and prognostically relevant abnormalities undetectable by fluorescence in situ hybridisation (Rigolin et al, 2015) , but also structural and numerical lesions that may predict a worse clinical outcome (Haferlach et al, 2007; Rigolin et al, 2012; Baliakas et al, 2014) .
We also found that the presence of unbalanced rearrangements was associated with a distinct mRNA expression profile with a deregulation of genes involved in cell cycle control and DNA damage response. Among these, TRPM4, RASGRF1, CTTNBP2 and SLAMF1 may be of interest as they may have possible prognostic and therapeutic implications. Transient receptor potential channel melastatin 4 (TRPM4) is an ion channel that plays a critical role in the control of the membrane potential, leading to the regulation of cell cycle, DNA replication, intracellular signal transduction and inflammatory responses. TRPM4 has been found up-regulated in diffuse large B-cell lymphomas, where it was associated with a significantly worse outcome (Loo et al, 2017) . RASGRF1 is a guanine exchange factor that plays a role in B-cell receptor (BCR) signalling. RASGRF1 has been found overexpressed in CLL and its activation was blocked by Bruton Tyrosine Kinase inhibitors (Liao et al, 2014) . Cortactin binding protein 2 (CTTNBP2) is an actin binding protein and Lyn substrate that is up-regulated in CLL patients and correlates to a poor prognosis, suggesting that this protein could be relevant in the pathogenesis and aggressiveness of the disease (Martini et al, 2017) . Finally, reduced SLAMF1 levels have been associated with clinical and molecular markers of unfavourable prognosis. SLAMF1 is involved in several pathways related to cell migration, cytoskeletal organization and intracellular vesicle formation. The loss of SLAMF1 expression may affect responses to therapeutic agents, such as fludarabine and the BCL2 homology domain 3 mimetic, ABT-737 (Bologna et al, 2016) .
In conclusion, we have shown that CLL patients with unbalanced rearrangements represent a subset of very highrisk CLL patients with distinct clinical and biological characteristics. These patients need to be identified at the time of treatment and should be considered upfront for alternative treatments, including combinations of novel agents. Table S1 . List of CK according to the presence of unbalanced rearrangements. Table S2 . List of consistently down-modulated and upmodulated genes identified in CLL samples of patients with and without unbalanced rearrangements Appendix S1. Materials and methods
